Neural cell adhesion molecule

Source: Wikipedia, the free encyclopedia.
(Redirected from
CD56
)
NCAM1
Ensembl
UniProt
RefSeq (mRNA)

NM_001081445
NM_001113204
NM_010875
NM_001311065

RefSeq (protein)

NP_000606
NP_001070150
NP_001229536
NP_001229537
NP_851996

NP_001074914
NP_001106675
NP_001297994
NP_035005
NP_001391651

Location (UCSC)Chr 11: 112.96 – 113.28 MbChr 9: 49.41 – 49.71 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Neural cell adhesion molecule (NCAM), also called CD56, is a homophilic binding glycoprotein expressed on the surface of

CD8+ T cells, as well as on dendritic cells.[5] NCAM has been implicated as having a role in cell–cell adhesion,[6]
neurite outgrowth, synaptic plasticity, and learning and memory.

Forms, domains and homophilic binding

NCAM is a glycoprotein of Immunoglobulin (Ig) superfamily. At least 27 alternatively spliced NCAM mRNAs are produced, giving a wide diversity of NCAM isoforms.

cytoplasmic
domain:

  • NCAM-120kDa (GPI anchored)
  • NCAM-140kDa (short cytoplasmic domain)
  • NCAM-180kDa (long cytoplasmic domain)

The extracellular domain of NCAM consists of five

immunoglobulin
-like (Ig) domains followed by two fibronectin type III (FNIII) domains. The different domains of NCAM have been shown to have different roles, with the Ig domains being involved in homophilic binding to NCAM, and the FNIII domains being involved signalling leading to neurite outgrowth.

Homophilic binding occurs between NCAM molecules on opposing surfaces (trans-) and NCAM molecules on the same surface (cis-)1. There is much controversy as to how exactly NCAM homophilic binding is arranged both in trans- and cis-. Current models suggest trans- homophilic binding occurs between two NCAM molecules binding antiparallel between all five Ig domains or just IgI and IgII. cis- homophilic binding is thought to occur by interactions between both IgI and IgII, and IgI and IgIII, forming a higher order NCAM multimer. Both cis- and trans- NCAM homophilic binding have been shown to be important in NCAM “activation” leading to neurite outgrowth.

Minor exons

Another layer of complexity is created by the insertion of other "minor" exons in the NCAM transcript. The two most notable are:

Posttranslational modification

NCAM exhibits

endoneuraminidase (EndoN) has been shown to abolish long-term potentiation (LTP) and long-term depression (LTD).[9][10][11]

Expression in normal cells

The neural cell adhesion molecule NCAM1 appears on early

embryonic cells and is important in the formation of cell collectives and their boundaries at sites of morphogenesis
.

Later in development, NCAM1 (CD56) expression is found on various differentiated tissues and is a major CAM mediating adhesion among neurons and between neurons and muscle.

Function

NCAM is thought to signal to induce neurite outgrowth via the

FGFR
) and act upon the p59Fyn signaling pathway.

In nerves, NCAM1 regulates homophilic (like-like) interactions between neurons and between neurons and muscle; it associates with

integrin receptors
, cells separate and migrate.

During

CD8+ T cells
.

In

embryonic development
.

Pathology

In

anatomic pathology, pathologists make use of CD56 immunohistochemistry
to recognize certain tumors.

  • Normal cells that stain positively for CD56 include
    neuroendocrine
    tissues.
  • Tumors that are CD56-positive are
    Ewing's sarcoma
    family of tumors.

Cancer

A member of the NCAM superfamily, NCAM2 gene has been observed progressively downregulated in

human papillomavirus-positive neoplastic keratinocytes derived from uterine cervical preneoplastic lesions at different levels of malignancy.[12] For this reason, NCAM2 is likely to be associated with tumorigenesis and may be a potential prognostic marker for uterine cervical preneoplastic lesions progression.[12]

Alzheimer's disease

NCAM2 is found in lower levels in hippocampal synapses of Alzheimer's disease sufferers and is found to be broken down by beta-amyloid.[13]

Rabies

NCAM has been identified as one of the target proteins for the rabies virus, allowing entry into the cell.[14]

Anti-NCAM therapy

NCAM has been used as a target molecule for experimental antibody-based immunotherapy. Successful radio-immunolocalisation of metastases was demonstrated after giving injections of NCAM-binding 123J-UJ13a or 131J-UJ13a radio-immunoconjugates to children with neuroblastoma. Patients with small cell lung cancer were treated with the anti-NCAM immunotoxin huN901-DM1 in two different clinical studies, revealing acceptable toxicity and signs of clinical response.[15]

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000149294Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000039542Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. PMID 28791027
    .
  6. ^ Pathology Outlines
  7. PMID 1996115
    .
  8. ^ .
  9. .
  10. .
  11. .
  12. ^ .
  13. .
  14. .
  15. .

External links

This page is based on the copyrighted Wikipedia article: CD56. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy